At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
Nepafenac +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Edema After Phacoemulsification: Prospective Randomized Double-masked Study
In Brief
A Phase 4 clinical trial evaluating Nepafenac and Ketorolac for Cystoid Macular Edema and Cataract. Completed, enrolled 40 participants across 1 site.
Detailed Summary
To compare the anti-inflammatory efficacy of ketorolac of tromethamine 0.4% and nepafenac 0.1% eye drops for prophylaxis of cystoid macular edema (CME) after small-incision cataract extraction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystoid Macular Edema, Cataract
CountriesBrazil
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
Primary CompletionAug 2013
Study CompletionFeb 2014
First PostedMar 2014
TodayJul 2026
First PostedMar 12, 2014
Enrollment StartAug 1, 2013
Primary CompletionAug 1, 2013
Study CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 12.3 years ago
Interventions
Nepafenacdrug
One drop in the study eye 3 times daily for 30 days
Ketorolacdrug
One drop in the study eye 4 times daily for 30 days